Envision Pharma Group (Envision) and Alucio have revealed plans for a global partnership to drive impactful, scientific exchange, while delivering additional value for life sciences customers.

The partnership will combine Envision’s extensive medical affairs experience and scientific content development understanding with Alucio’s established Beacon technology – a scientific omnichannel exchange platform – allowing for a broader scope of life sciences companies to assemble, refine and change scientific content easily, with its features that seamlessly support both virtual and in-person meetings with healthcare professionals (HCPs).

Alucio’s Beacon platform has been created as a contemporary cloud-based content activation and HCP engagement platform built specifically for optimising dialogue for medical science liaisons, medical affairs professionals and market access teams.

Through this collaboration, Envision will provide strategic, insight-driven communications expertise with agile content development approaches to assist medical affairs and market access teams to take full advantage of the Beacon platform and future Alucio technology products.

Dave Gulezian, Alucio co-founder and chief executive officer, said: “Envision is a recognised, global leader within the medical affairs space. We are very excited about the potential of this partnership to bring the benefits of our modern scientific exchange platform to an even broader network and establish best practice in the context of content development, deployment and engagement.

“We also look forward to collaborating to identify new opportunities to address emerging customer needs.”

From a macro perspective, the global partnership between the two companies offers the chance to transform currently accepted industry standards in stakeholder engagement by redefining what qualifies as best practice content development processes and leveraging technology, in order to create powerful and tailored scientific exchanges.

The companies will seek to enhance and integrate technology solutions that deliver real-time data and analytics through a user-centric approach, to better inform strategy and aid customer decision-making.

Envision’s chief executive officer, Meg Heim, shared her thoughts on the collaboration: “We have been impressed with what Alucio has built with Beacon and the momentum they have generated within the medical affairs space.

“We’re equally excited to align our medical strategy, agile content development and communications expertise with Alucio’s technology capabilities to further enhance our customers’ stakeholder engagement through a personalised, omnichannel approach.”

Meg Heim

Dave Gulezian

Lumanity has announced its acquisition of Endpoint Outcomes (Endpoint), a company specialising in harnessing the voice of patients to document the impact of treatments on health-related quality of life. The highly complementary acquisition of Endpoint strengthens Lumanity’s value demonstration capabilities by creating a comprehensive, global health economics and outcomes research suite of services.

Commenting on the acquisition, Chris Evans, chief executive officer of Endpoint, said: “We are excited to join Lumanity and proud to be part of a company with a purpose that aligns with our own. We believe that joining Lumanity is the next step in this journey, allowing us to continue to keep patients at the heart of everything we do.”

Endpoint works in the development and implementation of patient-centric clinical outcomes assessments (COAs) and, with its team of experts, serves its clients by helping to define the value of new medical innovations and generate evidentiary support of the highest calibre for regulators, clinicians, payers and patients.

Lumanity’s aim of demonstrating the value of medical advances to optimise patient access, which requires the consideration and integration of economic, patient and clinical outcomes, is bolstered by the addition of Endpoint’s proven record of COA capability.

The need for a convergence of health economics and patient-centred outcomes research is vital to support payer evaluations and health technology assessments for Lumanity’s clients.

Lumanity was formed by bringing together the expertise and capabilities of various organisations, including Guidemark Health, Cello Health, BresMed, Cyan Health, Zipher Medical Affairs and Innovative Edge.

Incorporating Endpoint reinforces Lumanity’s unique and diverse collection of experienced industry pioneers, data luminaries, subject matter experts and problem solvers with advanced clinical, scientific and functional capabilities.

Jon Williams, chief executive officer of Lumanity, said: “We are thrilled to welcome Endpoint as part of Lumanity. We were immediately impressed with the strength of the team, the quality of Chris’s leadership and how well our views aligned on the strategic opportunities available to us as a combined force.

“We look forward to working with our new colleagues to define and build market-leading, patient-centred research services to address both HTA and payer needs, and we are confident that our work will yield innovative new solutions for our clients and partners.”

Jon Williams

Chris Evans